Association of higher plasma vitamin d binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: Cause of a functional Vitamin D deficiency?

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5619-5628

  Havens, Peter L ^a   Kiser, Jennifer J ^b   Stephensen, Charles B ^c   Hazra, Rohan ^d   Flynn, Patricia M ^e   Wilson, Craig M ^f   Rutledge, Brandy ^g   Bethel, James ^g   Pan, Cynthia G ^a   Woodhouse, Leslie R ^c   Van Loan, Marta D ^c   Liu, Nancy ^g   Lujan Zilbermann, Jorge ^h   Baker, Alyne ⁱ   Kapogiannis, Bill G ^d   Gordon, Catherine M ^j   Mulligan, Kathleen ^k  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c USDAWestern Human Nutrition Research Center   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g WESTAT   (United States)

^h UNIVERSITY OF SOUTH FLORIDA   (United States)

ⁱ TULANE UNIVERSITY   (United States)

^j BROWN UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; PARATHYROID HORMONE; PHOSPHATE; TENOFOVIR DISOPROXIL; VITAMIN D BINDING PROTEIN;

ADULT; AFRICAN AMERICAN; ANTIVIRAL THERAPY; ARTICLE; BONE TURNOVER; CALCIUM BALANCE; CALCIUM BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRINKING BEHAVIOR; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE URINE LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CALCITRIOL; CALCIUM; DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HIV; HIV INFECTIONS; HUMANS; HYPOPHOSPHATEMIA; MALE; ORGANOPHOSPHONATES; PARATHYROID HORMONE; PHOSPHATES; REVERSE TRANSCRIPTASE INHIBITORS; VITAMIN D DEFICIENCY; VITAMIN D-BINDING PROTEIN;

EID: 84885909493     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01096-13     Document Type: Article

References (50)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernandez T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker L-G, Mayer KH, Kallas EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng J-H, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
2. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, 903 Study Group. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201.
3. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL. 2006. Tenofovir disoproxil fumarate and an optimized background regimen of antiretoviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118:e711-e718.
4. Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL. 2005. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 116:e846-e854.
5. Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A. 2009. Simplification of antiretroviral therapy with tenofoviremtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin. Infect. Dis. 49:1591-1601.
6. Stellbrink H-J, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H, ASSERT Study Group. 2010. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin. Infect. Dis. 51:963-972.
7. Judd A, Boyd KL, Stohr W, Dunn D, Butler K, Lyall H, Sharland M, Shingadia D, Riordan A, Gibb DM. 2010. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 24:525-534.
8. Kinai E, Hanabusa H. 2005. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS 19: 2031-2033.
9. Kinai E, Hanabusa H. 2009. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res. Hum. Retrovir. 25:387-394.
10. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, Cuenca L, Gonzalez-Pardo G, Khoo S, Back D, Owen A. 2009. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin. Infect. Dis. 48: e108 -116.
11. Buchacz K, Brooks JT, Tong T, Moorman AC, Baker RK, Holmberg SD, Greenberg A, HIV Outpatient Study (HOPS) Investigators. 2006. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med. 7:451-456.
12. Essig M, Duval X, Kaied FA, Iordache L, Gervais A, Longuet P, Blanchet F, Peytavin G, Leport C. 2007. Is phosphatemia the best tool to monitor renal tenofovir toxicity? J. Acquir. Immune Defic. Syndr. 46:256-258.
13. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, Rivas P, Albalater M, Blanco F, Moreno V, Vispo E, Soriano V. 2009. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 23:689-696.
14. Maggi P, Montinaro V, Bellacosa C, Pietanza S, Volpe A, Graziano G, Strippoli GFM, Angarano G. 2012. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS Patient Care Stds. 26:5-11.
15. Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H, Swiss HIV Cohort Study. 2008. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV cohort study. Antivir. Ther. 13: 1077-1082.
16. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, Edwards SG, Johnson MA, Connolly JO. 2009. Tenofovir-associated renal and bone toxicity. HIV Med. 10:482-487.
17. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. 2011. Tenofovir nephrotoxicity: 2011 update. AIDS Res. Treatment 2011:354908.
18. Bech A, Van Bentum P, Nabbe K, Gisolf J, Richter C, De Boer H. 2012. Fibroblast growth factor 23 in hypophosphataemic HIV-positive adults on tenofovir. HIV Med. 13:558-563.
19. Saidenberg-Kermanac'h N, Souabni L, Prendki V, Prie D, Boissier M-C. 2011. Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. Joint Bone Spine 78:306-308.
20. Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, Hay PE, Pakianathan MR, Sadiq ST. 2010. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J. Acquir. Immune Defic. Syndr. 54:496-499.
21. Masiá M, Padilla S, Robledano C, López N, Ramos JM, Gutierrez F. 2012. Short communication: early changes in parathyroid hormone concentrations in patients initiating antiretroviral therapy with tenofovir. AIDS Res. Hum. Retrovir. 28:242-246.
22. Institute of Medicine. 2011. Dietary reference intakes for calcium and vitamin D. National Academies Press, Washington, DC.
23. Childs KE, Fishman SL, Constable C, Gutierrez JA, Wyatt CM, Dieterich DT, Mullen MP, Branch AD. 2010. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res. Hum. Retrovir. 26:855-859.
24. Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Mulligan K, Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 Study Team. 2012. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin. Infect. Dis. 54:1013-1025.
25. Bech A, Van Bentum P, Telting D, Gisolf J, Richter C, De Boer H. 2012. Treatment of calcium and vitamin D deficiency in HIV-positive men on tenofovir-containing antiretrovial therapy. HIV Clin. Trials 13:350-356.
26. Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC. 2005. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 49:1898-1906.
27. Zolopa A, Ortiz R, Sax P, Brar I, Elion R, Wang H, Callebaut C, Ramanathan S, Fordyce M, McCallister S. 2013. Comparative study of tenofovir alafenamide versus tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. Abstr. 20th Conf. Retrovir. Opportun. Infect., abstr 99LB.
28. Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team. 2012. Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J. Clin. Endocrinol. Metab. 97:4004-4013.
29. King T, Bushman L, Kiser J, Anderson PL, Ray M, Delahunty T, Fletcher CV. 2006. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 843:147-156.
30. Cummings SR, Block G, McHenry K, Baron RB. 1987. Evaluation of two food frequency methods of measuring dietary calcium intake. Am. J. Epidemiol. 126:796-802.
31. Delahunty T, Bushman L, Fletcher CV. 2006. Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830:6-12.
32. Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL, Adolescent Trials Network for HIV/AIDS Interventions. 2008. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 52:631-637.
33. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration. 2006. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Int. Med. 145:247-254. [Erratum, 149:519, 2008.]
34. Bikle DD, Siiteri PK, Ryzen E, Haddad JG. 1985. Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J. Clin. Endocrinol. Metab. 61:969-975.
35. Laing CJ, Cooke NE. 2005. Vitamin D-binding protein, p 117-134. In Feldman D, Glorieux FH, Pike JW (ed), Vitamin D, 2nd ed, vol 2. Elsevier Academic Press, Boston, M.A.
36. Speeckaert M, Huang G, Delanghe JR, Taes YE. 2006. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin. Chim. Acta 372:33-42.
37. Pattanaungkul S, Riggs BL, Yergey AL, Vieira NE, O'Fallon WM, Khosla S. 2000. Relationship of intestinal calcium absorption to 1,25-dihydroxyvitaminD[1, 25(OH)2D] levels in young versus elderly women: evidence for age-related intestinal resistance to 1,25(OH)2D action. J. Clin. Endocrinol. Metab. 85:4023-4027.
38. St John A, Thomas MB, Davies CP, Mullan B, Dick I, Hutchison B, van der Schaff A, Prince RL. 1992. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitaminDlevels in mild and moderate renal failure. Nephron 61:422-427.
39. Fux CA, Christen A, Zgraggen S, Mohaupt MG, Furrer H. 2007. Effect of tenofovir on renal glomerular and tubular function. AIDS 21:1483-1485.
40. Peacock M. 2002. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J. Bone Miner. Res. 17(Suppl 2):N87-N94.
41. Marks KH, Kilav R, Naveh-Many T, Silver J. 1996. Calcium, phosphate, vitamin D, and the parathyroid. Pediatr. Nephrol. 10:364-367.
42. Gupta SK, Shen C, Moe SM, Kamendulis LM, Goldman M, Dubé MP. 2012. Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One 7:e45716. doi: 10.1371/journal.pone. 0045716.
43. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM. 2011. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin. J. Am. Soc. Nephrol. 6:383-389.
44. Martin A, David V, Quarles LD. 2012. Regulation and function of the FGF23/klotho endocrine pathways. Physiol. Rev. 92:131-155.
45. Bergwitz C, Juppner H. 2010. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu. Rev. Med. 61:91-104.
46. Uzum AK, Salman S, Telci A, Boztepe H, Tanakol R, Alagol F, Ozbey NC. 2010. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur. J. Endocrinol. 163:825-831.
47. Coca S, Perazella MA. 2002. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am. J. Med. Sci. 324:342-344.
48. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. 2010. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin. Infect. Dis. 51:496-505.
49. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF. 2007. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21:1273-1281.
50. Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, Faucher O, Lacarelle B. 2012. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J. Acquir. Immune Defic. Syndr. [Epub ahead of print.] doi:10 .1097/QAI.0b013e31827ce4ee.